Alnylam Pharmaceuticals Inc
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$572.00 | Bgmgmk | Pcdjwmzl |
Alnylam Reports Positive Phase 3 Results for Patisiran; Raising FVE to $199 on Improved Outlook
Narrow-moat Alnylam announced positive top-line results from the APOLLO-B Phase 3 study of its investigational RNAi therapeutic candidate, patisiran, to treat patients with ATTR amyloidosis with cardiomyopathy. Investors reacted quite favorably to the good news and sent the stock up over 49%. We’ve updated our model to reflect an improved outlook based on the positive results, and we’ve raised our fair value estimate to $199 per share from $158. We view shares as fairly valued, currently trading in 3-star territory. We maintain our narrow economic moat rating and positive trend.